Objective: To describe the clinical and serological features of a prospectively followed cohort of early diagnosed systemic lupus erythematosus (SLE) patients during a one-year follow-up period. Methods: SLE patients with disease duration less than 12 months were consecutively enrolled in a multicentre, prospective study. At study entry and then every 6 months, a large panel of data was recorded. Results: Of 260 patients enrolled, 185 had at least 12 months of follow-up; of these, 84.3% were female, 92.4% were Caucasians. Mean diagnostic delay was about 20 months; higher values of European Consensus Lupus Activity Measurement (ECLAM) and of organs/systems involved were both associated with shorter diagnostic delay. Clinical and serological parameters improved after study entry. However, patients' quality of life deteriorated and cardiovascular risk factors significantly increased. About one-third of patients with active disease at study entry went into remission (ECLAM ¼ 0). Negative predictors for remission were: oral ulcers, arthritis, low C4, anti-SSB (Ro) antibodies and therapy with mycophenolate. There was a widespread use of glucocorticoids both at baseline and during follow-up. Conclusion: Clinical symptoms and serological parameters improve during the first period after diagnosis. However, patients' quality of life deteriorates. The widespread use of glucocorticoids is probably the reason for the early significant increase of some cardiovascular risk factors.
Systemic lupus erythematosus (SLE) is a disease characterized by a broad spectrum of clinical manifestations and a multitude of laboratory abnormalities. The complexity of the disease could also explain why it can be difficult to identify SLE patients in an early stage of the disease. In fact, there are no pathognomonic clinical or serological features that can help clinicians in making an SLE diagnosis. Criteria for the classification of SLE were elaborated by the American College of Rheumatology (ACR) firstly in 1971, and then revised in 1982 and again in 1997. 1 The new Systemic Lupus International Collaborating Clinics (SLICC) classification criteria seem to perform better than the revised ACR criteria in terms of sensitivity but not specificity. 2 The SLICC criteria are meant to be clinically more relevant, allowing the inclusion of more patients with clinically defined lupus than are included using the current ACR criteria. However, even the SLICC classification criteria are not diagnostic criteria, and cannot be applied to every individual case.
So, the diagnosis of SLE remains very difficult, especially in the early stage of the disease, when it is more important to start the correct treatment, since it is well known that a delay in treatment is associated with a worse prognosis. [3] [4] [5] The progressive decrease in the time elapsed between disease onset and diagnosis is one of the major contributors to the improvement of survival 6 and quality of life 7 in SLE patients over time.
In 2012, we started a multicentre, prospective study on patients with recent (less than 12 months) onset SLE coming from nine Italian centres, with the purpose of collecting information on the clinical and laboratory characteristics of SLE Caucasian patients at the beginning of the disease and during the first years of follow-up. Data on the clinical and serological characteristics of this cohort at the time of patients' enrolment have already been published. 8 In this paper, we describe the clinical and serological features obtained after a 1-year follow-up period of this inception cohort and compare it with the information obtained at enrolment. In addition, we provide information on factors affecting the diagnostic delay of patients enrolled, on remission at the 12-month follow-up visit and factors correlated, on drug therapy both at baseline and follow-up, and on the differences between patients persistently anti-dsDNA negative and patients who are anti-dsDNA positive.
Patients and methods
This is a multicentre, prospective study. Nine Italian centres with longstanding experience in Lupus management are involved. All patients with a diagnosis of SLE according to the 1997 ACR Classification Criteria 1 and a disease duration (from diagnosis until study entry) lower than 12 months were consecutively enrolled in the study. The study started on 1 January 2012 and was approved by the Review Board of the Coordinator Centre (Comitato Etico Azienda Ospedaliero Universitaria di Cagliari protocol number NP/2012/1312). Patients' written informed consent to participate in the study and to publish the results was obtained at the time of enrolment.
In this paper we report on patients enrolled until the end of June 2017.
Information on demographic characteristics, medical history, clinical symptoms, physical examinations, laboratory results, disease activity, disease damage and patients' quality of life, at entry into the study and then every 6 months, were recorded. Study data were collected and managed using REDCap electronic data capture tools hosted at the Italian Society for Rheumatology. 9 Global SLE disease activity was measured by the European Consensus Lupus Activity Measurement (ECLAM) index, a validated measure of disease activity in SLE. 10, 11 Clinical remission was defined by ECLAM score ¼ 0. Cumulative damage was scored according to the SLICC damage index, a validated measure to assess damage in SLE. 12 Patients' quality of life was estimated by means of a visual analogue scale (VAS).
Autoantibody assessment
Autoantibodies were measured locally in each participating centre. The following autoantibodies were considered in this study: antinuclear antibodies (ANA), anti-dsDNA, anti-SSA (Ro), anti-SSB (La), anti-Sm, anti-RNP, anticardiolipin (aCL), anti-beta2 glycoprotein I (anti-beta2GPI) and lupus anticoagulant (LA). ANA were measured by immunofluorescence using Hep2 cells as substrate. Anti-dsDNAs were measured either by immunofluorescence using the Crithidia luciliae or Farr technique. Anti-SSA, anti-SSB, anti-Sm and anti-RNP were measured either by immunoblot technique or ELISA. Anticardiolipin antibodies and anti-beta2GPI were measured by ELISA. LA was measured by coagulometric assay. Concerning aCL and anti-beta2GPI, patients were considered to be positive when either IgG or IgM (or both) were present at medium-high titer.
Statistical analysis
Results of the analysis of continuous variables are indicated as mean AE SD or median and range, as appropriate. Conventional v 2 and Fisher's exact tests were used to analyse qualitative differences between independent samples. The McNemar test was used to analyse qualitative differences between patients at enrolment and after a 1-year follow-up period. Student's t-test and Wilcoxon test were used to analyse mean differences. A p value < 0.05 was taken to indicate statistical significance. The relationship between clinical and therapeutic variables with 12-months remission according to ECLAM was analysed by logistic model, and results presented as odds ratios (ORs) and 95% confidence intervals (CIs). All the analyses were performed using R statistical environment (the R project for statistical computing, https://www.rproject.org).
Results
At the end of June 2017, 260 patients were enrolled, of whom 185 had at least 12 months of follow-up. The cohort of these 185 patients was composed by 156 (84.3%) females, and the majority (92.4%) were Caucasians. Mean age (SD) of patients at study entry was 37.92 (15.01) years, mean age at disease onset (first symptom of SLE) was 36.01 (15) 
Diagnostic delay (from first symptom to diagnosis of SLE)
Mean diagnostic delay (from symptom onset until diagnosis) was about 20 months for the cohort of 185 patients. There were 126 (68.48%) patients with a diagnostic delay < 1 year, 41 (22.28%) with a diagnostic delay between 1 and 5 years, and 17 (9.24%) with a diagnostic delay > 5 years. Then, we analysed the impact of the clinical and laboratory characteristics on the diagnostic delay. We found that mean value of ECLAM and mean number of organ/system involvement were both associated with a shorter diagnostic delay in the three groups (p ¼ 0.02 and p ¼ 0.01, respectively). On the contrary, diagnostic delay was not associated with age, gender, familiarity for SLE or pattern of clinical presentation.
No single ACR criterion as a first symptom of SLE was associated with the delay in diagnosis. However, two patterns of combined organ/system involvement were found to be associated with longer diagnostic delay: patients with concomitant musculoskeletal and cardiorespiratory involvement (p ¼ 0.05) and those with concomitant mucocutaneous and haematological involvement (p ¼ 0.03).
In addition, we analysed the frequency of SLE autoantibodies in the various combined organ/ system pattern of presentation of the disease. Anti-RNP antibodies were significantly more represented in patients presenting with concomitant mucocutaneous, musculoskeletal and haematological symptoms (53.8 vs 19.6% in patients with different patterns of presentation, p ¼ 0.009). aCL (medium-high titer) were significantly increased in those presenting with concomitant musculoskeletal and haematological symptoms (60 vs 26.9% in patients with other patterns of presentation, p ¼ 0.03).
Cumulative frequency of the manifestations included in the ACR classification criteria until study entry and during 12 months of follow-up
The cumulative frequencies (patients who ever had the symptom) until enrolment and during 12 months of follow-up of the manifestations included in the ACR classification criteria are reported in Figure 1 . Compared with study entry, there was an increase of the frequency of all these manifestations, and this was statistically significant for malar rash (p ¼ 0.02).
The combined frequencies of the mucocutaneous classification criteria were 54% at study entry and 58.2% at the end of the 12-month follow-up period, confirming that they are among the most common clinical manifestations included in the ACR classification criteria both at SLE onset and during the first 12 months of disease.
ANA were present in all but two patients at enrolment, both having anti-Ro antibodies.
Frequency of clinical symptoms and immunological features at study entry and during 12 months of follow-up
The frequencies of the clinical and serological features of this cohort of patients at the enrolment visit and during the first 12 months after study entry are reported in Figures 2 and 3 . Following study entry, there was a marked improvement of the disease: patients underwent a significant decrease in all the clinical manifestations, C3 and C4 level significantly improved and anti-dsDNA antibody positive patients significantly decreased.
In agreement, the median (interquartile range) ECLAM score decreased from 2.5 (1-4.5) at study
entry to 1 (0-2) at the 12-month visit (p < 0.001). However, median (interquartile range) patients' quality of life (VAS) decreased, albeit not significantly, from 54 (40-70) to 50 (30-71.5, p ¼ 0.43).
Mean number (SD) of hospitalizations decreased from 1.3 (1.2) until study entry to 0.5 (1.7) during the first 12 months after study entry (p < 0.001). We observed 82 patients without clinical symptoms at the 12-month follow-up visit. According to the definition of remission proposed by Doria et al., 13 of these 82 patients, no patient was in complete remission (no clinical symptom, normal serology, no prednisone and no immunosuppressants). Eight patients were in clinical remission without prednisone (no clinical symptom, abnormal serology and immunosuppressants allowed). Forty patients were in clinical remission with no more than 5 mg prednisone daily (no clinical symptom, abnormal serology and immunosuppressants allowed), whereas 21 patients in clinical remission were taking more than 5 mg prednisone daily. Thirteen (15.8%) patients were not evaluated due to missing information. 
Drug therapy at study entry and during 12 months of follow-up
Drug therapy at study entry and during 12 months of follow-up is reported in Figure 4 . Widespread use of glucocorticoids in lupus patients, both at study entry (85.4%) and at follow-up (89.2%), is evident compared with other immunosuppressive drugs. Hydroxychloroquine was also given to a high proportion of patients (64.9% at study entry and 76.5% at follow-up, p ¼ 0.004). Compared with the baseline, there was a significant increase in patients taking azathioprine and mycophenolate Early Italian SLE cohort GD Sebastiani et al.
glucocorticoids
(93.2%), hydroxychloroquine (81.4%) and, less frequently, azathioprine (11.9%), mycophenolate (18.6%), cyclophosphamide (8.5%), methotrexate (8.5%) and cyclosporin A (5.1%).
SLE patients persistently anti-dsDNA negative
There were 21 (11.35%) patients who were persistently anti-dsDNA antibody negative. Even though they represent a small subcohort, we looked at possible differences with SLE patients who were antidsDNA positive at least once between baseline and the 12-month follow-up visit. The two subgroups had similar sociodemographic characteristics and similar frequency of the various comorbidities. However, patients persistently anti-dsDNA negative more often had discoid rash and photosensitivity both at baseline and during follow-up (p < 0.001), whereas they had less renal involvement at follow-up (p ¼ 0.03), less reduction of C3 both at baseline and during follow-up (p ¼ 0.01), and were less likely to be treated with prednisone both at baseline (p ¼ 0.03) and during follow-up (p ¼ 0.01) when compared with anti-dsDNA positives (Table 1) .
Baseline disease activity was higher, albeit not significantly, in anti-dsDNA positive patients (ECLAM 3.3 (2.5) vs 2.4 (1.6)). Accordingly, antidsDNA positive patients were more likely to be hospitalized during the follow-up period (mean number of hospitalizations 0.6 (1.9) in antidsDNA positives vs 0.05 (0.2) in anti-dsDNA negatives, p ¼ 0.05). During follow-up, the mean number of pregnancies was higher in anti-dsDNA negative patients (1.3 (1.1)) when compared with anti-dsDNA positive patients (0.8 (1.2), p ¼ 0.03).
Discussion
The diagnosis of SLE remains very difficult, especially in the early stage of the disease, when it is more important to start the correct treatment, since it is well known that a delay in treatment is associated with a worse prognosis. [3] [4] [5] The progressive decrease in the time elapsed between disease onset and diagnosis is one of the major contributors to the improvement of survival 6 and quality of life 7 in SLE patients over time.
With the purpose of collecting information on the clinical and laboratory characteristics of SLE patients at the beginning of the disease and during the first years of follow-up, on behalf of the Italian Society of Rheumatology, a multicentre, prospective study on patients with recent (less than 12 months) onset SLE coming from nine Italian centres was started in January 2012. Before starting the study, we discussed whether to consider the date of diagnosis as the time when patients reached the minimum for being classified as affected by SLE (according to ACR criteria), or the time when the 'clinical' diagnosis had been made. In order to collect a more homogeneous cohort, we chose to considered it to be the date of diagnosis the time of classification (four or more ACR classification criteria).
Preliminary data on the clinical and serological characteristics of this cohort at the time of patients' enrolment have already been published. 8 In this paper, a further analysis of the 185 patients who had at least 12 months of follow-up is reported. Our data show that the mean diagnostic delay (from the appearance of the first symptom until the diagnosis) was about 20 months in this cohort. The majority (68.5%) of patients were diagnosed no later than 12 months, 22.3% had the diagnosis in a period ranging from 1 to 5 years and 9.2% at least 5 years after the appearance of the first symptoms. The number of organs/systems involved and disease activity (ECLAM) at onset were significantly associated with an early recognition of disease (p ¼ 0.01 and 0.02, respectively). On the contrary, patients with contemporary mucocutaneous and haematological involvement, and those with the combination of musculoskeletal and cardiorespiratory involvement, experienced a significant delay in diagnosis (p ¼ 0.02 and 0.05, respectively). These findings may suggest that the disease is more easily recognizable when it is more active and involves more organs/systems. On the other hand, the correct diagnosis can be missed when there is little awareness of the disease and when the patient is not seen by a multidisciplinary team devoted to SLE management.
The most frequent symptoms at presentation were arthritis and mucocutaneous and haematological involvement. Malar rash and discoid lesions, which are more specific for SLE, were observed in less than one-third of cases. Thus, the majority of patients present with poorly specific symptoms, making prompt and correct diagnosis more difficult.
When comparing baseline with 12-month followup data, it appears that clinical manifestations and disease activity laboratory indexes all decreased significantly. Accordingly, there was a significant decrease in disease activity and in the number of hospitalizations. However, therapy was not effective in improving the quality of life, which showed a trend towards deterioration, suggesting that much effort is needed to improve our understanding of the needs of our patients.
In addition, cardiovascular risk factors such as obesity and dyslipidemia showed a significant increase during the 12-month follow-up period, and glucocorticoids were still taken by the large majority of patients at the 12-month follow-up visit, in contrast with the marked amelioration of disease symptoms and laboratory indexes. Cardiovascular risk factors and glucocorticoids are both associated with a worse prognosis in lupus patients, being negative factors for long-term morbidity and mortality. [14] [15] [16] By contrast, hydroxychloroquine seems to have a beneficial effect on damage accrual and long-term prognosis in SLE, 17, 18 and the monoclonal antibody belimumab is associated, among other beneficial effects, with steroid sparing. 19, 20 In Table 2 , the therapy of SLE patients from other observational lupus cohorts is reported, confirming that glucocorticoids are too frequently given to lupus patients across several countries. These data suggest that clinicians should frequently and carefully assess their therapeutic strategies for lupus patients, try to avoid or minimize steroid usage, and take advantage of safer drugs.
The definition of remission is a difficult task in SLE, and studies on this argument are currently ongoing. 13, [27] [28] [29] When talking about remission in SLE, one should take into account clinical parameters, serological parameters, therapy and duration. However, for the purpose of this study, we defined a patient in remission when ECLAM was '0'. About one-third of our patients were in remission (ECLAM activity index ¼ 0) at the 12-month follow-up visit. Baseline factors predictive of lack of remission were the presence of oral ulcers, arthritis, low C4 levels, anti-SSB (La) antibodies and being on mycophenolate.
A group of patients was persistently anti-dsDNA negative. When compared with anti-dsDNA positive patients, they had a less severe disease, both at baseline and during follow-up, thus confirming that anti-dsDNA antibody is a useful marker for discriminating patients with more aggressive disease. 30 In addition, the number of anti-dsDNA negative patients with a decreased C4 level remained quite stable, while normalization was more frequent in anti-dsDNA positive patients. Even if this finding is difficult to explain, it could probably be due to more aggressive treatment in anti-dsDNA positive patients.
This study has the following limitations: (a) patients have been enrolled only in rheumatological centres, thus conferring a possible selection bias, (b) laboratory examinations were not centralized, and (c) some differences with other early lupus cohorts, for instance in the time period chosen for the definition of 'early' disease and in the indexes utilized for measuring disease activity, make the comparison of our data with those from others less reliable.
In conclusion, even if relevant progress in SLE diagnosis has been made in the recent decades, mainly because of the widespread introduction of the ANA test by indirect immunofluorescence during the early eighties, a significant number of patients experience a delay in diagnosis greater than 12 months, and no significant reduction of the time elapsing from onset and diagnosis has been achieved over recent years.
The complex aetiopathogenesis and heterogeneous clinical manifestations cause SLE to be misdiagnosed not infrequently. This heterogeneity is a reason why a treatment may have beneficial effects in only a subset of patients. Identifying new SLE biomarkers might be a useful tool to subclassify patients, quantify the risk of organ involvement and predict the clinical manifestation that they might develop, as well as assign them the most appropriate treatment. It may also facilitate early and accurate SLE diagnosis and improve the evaluation of medications in clinical trials. Therefore, finding new specific biomarkers is very important and there is constant effort to obtain new and more valid tests for better management of the disease.
Our data show that the cumulative frequencies of the characteristics included in the current classification criteria are changing over time, and that this should be taken into account when elaborating 
